In this piece, we will take a look at the five healthcare stocks to invest in today according to Stanley Druckenmiller. To learn more about the famous investor and discover more stocks, take a look at the 9 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller.
5. Oscar Health, Inc. (NYSE:OSCR)
Duquesne Family Office’s Stake Value: $7.8 million
Percentage of Duquesne Family Office’s 13F Portfolio: 0.28%
Number of Hedge Fund Holders: 19
Oscar Health, Inc. (NYSE:OSCR) is a health insurance provider based out of New York, New York, United States. Its insurance products cover individuals, small families, and Medicare. Additionally, it also has a platform that allows providers and clients to interact with each other.
Mr. Druckenmiller’s Q4 2021 stake in Oscar Health, Inc. (NYSE:OSCR) was worth $7.8 million and it came in the form of 994,289 shares. During the same time period, 19 of the 924 hedge funds polled by Insider Monkey had invested in the firm.
For its fiscal fourth quarter, Oscar Health, Inc. (NYSE:OSCR) reported $496 million in revenue and -$0.95 in GAAP EPS, for a weak set of results that missed analyst estimates for both metrics. Goldman Sachs increased its price target to $9 from $6.5 in February 2022, outlining that a capital raise improves the company’s prospects.
Oscar Health, Inc. (NYSE:OSCR)’s largest investor is Joshua Kushner’s Thrive Capital which owns 37 million shares worth $295 million.
4. AbCellera Biologics Inc. (NASDAQ:ABCL)
Duquesne Family Office’s Stake Value: $9.4 million
Percentage of Duquesne Family Office’s 13F Portfolio: 0.34%
Number of Hedge Fund Holders: 18
AbCellera Biologics Inc. (NASDAQ:ABCL) is a Canadian biotechnology firm headquartered in Canada. It takes a unique approach to drug development, via searching a database of natural immune systems for finding new antibodies which can be developed into drugs.
For its fiscal Q4, AbCellera Biologics Inc. (NASDAQ:ABCL) raked in $139 million in revenue and $0.19 in GAAP EPS, beating analyst estimates for both metrics. Piper Sandler lowered its price target to $28 from $33 in February 2022, outlining that the company has reduced the pace of its program selectivity.
Duquesne Family Office held 659,750 AbCellera Biologics Inc. (NASDAQ:ABCL) shares as the fourth quarter of last year came to an end. These were worth $9.4 million and they represented 0.34% of its investment portfolio. Insider Monkey took a look at 924 hedge funds holdings for Q4 2021 and discovered that 18 had bought the company’s shares.
Julian Baker and Felix Baker’s Baker Bros. Advisors is AbCellera Biologics Inc. (NASDAQ:ABCL) ‘s largest investor. It has a $149 million stake that comes via 10 million shares.
3. Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
Duquesne Family Office’s Stake Value: $10.7 million
Percentage of Duquesne Family Office’s 13F Portfolio: 0.38%
Number of Hedge Fund Holders: 13
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is a biopharmaceutical firm that develops treatments for patients with life threatening diseases. These include neurological, kidney, and other diseases.
As the fourth quarter of last year came to an end, Duquesne Family Office had owned 406,264 Reata Pharmaceuticals, Inc. (NASDAQ:RETA) shares which were worth $10.7 million and represented 0.38% of its investment portfolio. Insider Monkey’s 924 hedge fund survey during the same time period revealed that 13 had also owned the company’s shares.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) reported $0.93 million in revenue and -$1.59 in non-GAAP EPS, in a huge miss that saw the company fall short of Wall Street revenue estimates by $830,000. Goldman Sachs set a $91 price target for the company in March 2022, stating that it has confidence in a drug following positive data.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA)’s largest shareholder is Israel Englander’s Millennium Management which owns 608,951 shares that are worth $16 million.
2. Option Care Health, Inc. (NASDAQ:OPCH)
Duquesne Family Office’s Stake Value: $33.8 million
Percentage of Duquesne Family Office’s 13F Portfolio: 1.22%
Number of Hedge Fund Holders: 26
Option Care Health, Inc. (NASDAQ:OPCH) is an infusion services provider. Its products cover heart diseases, Crohn’s disease, arthritis, sclerosis, and other inflammatory diseases.
For its fiscal fourth quarter, Option Care Health, Inc. (NASDAQ:OPCH) reported $927 million in revenue and $0.41 in GAAP EPS, for a strong set of results that beat analyst estimates for both. Deutsche Bank raised the company’s price target to $32 from $23.50 in November 2021, stating that the company has strong fundamentals.
Mr. Druckenmiller held a $33.8 million stake in Option Care Health, Inc. (NASDAQ:OPCH) during Q4 2021, which came in the form of 1.1 million shares. Insider Monkey scanned 924 hedge fund holdings for the same time period and discovered that 26 had also held a stake in the company.
Option Care Health, Inc. (NASDAQ:OPCH)’s largest investor is Peter S. Park’s Park West Asset Management which owns $5.7 million shares worth $164 million.
1. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Duquesne Family Office’s Stake Value: $41 million
Percentage of Duquesne Family Office’s 13F Portfolio: 1.5%
Number of Hedge Fund Holders: 17
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is an American surgical robotics company headquartered in Redwood City, California. It develops and sells an image guided surgical robotic system that aids surgeons during urethra surgery.
Duquesne Capital owned 1.6 million PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares as the fourth quarter of 2021 came to an end. These were worth $41 million and represented its largest healthcare holding. A Q4 2021 924 hedge fund survey conducted by Insider Monkey revealed that 17 had bought the company’s shares.
By the end of its fiscal fourth quarter, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) reported $10 million in revenue and -$0.42 in GAAP EPS, beating analyst revenue estimates but missing them for EPS. Guggenheim lowered its price target to $40 from $55 in March 2022, stating that the reduction is due to multiple compression.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT)’s largest shareholder is Andreas Halvorsen’s Viking Global which owns 4.9 million shares worth $122 million.
Disclosure: None. You can also take a look at 10 Best Growth Stocks Under $10 and 12 Best Large-cap Biotech Stocks To Buy Now.
